Lexeo Therapeutics, Inc. Capital Expenditures
Lexeo Therapeutics, Inc. (LXEO) reported Capital Expenditures of $42.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-12
- Lexeo Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $7.00K.
- Lexeo Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $35.00K.
- Lexeo Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $0.00.
- Lexeo Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $289.00K, a 248.19% increase year-over-year.
- Lexeo Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $397.00K, a 17.46% decline from fiscal 2024.
- Lexeo Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $481.00K, a 318.26% increase from fiscal 2023.
- Lexeo Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $115.00K, a 82.89% decline from fiscal 2022.
- Lexeo Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $672.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $42.00K 10-Q · filed 2026-08-12 | $42.00K derived: sum of 3 quarters · filed 2026-08-12 | $331.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $35.00K 10-Q · filed 2026-05-11 | $35.00K derived: sum of 2 quarters · filed 2026-05-11 | $324.00K derived: sum of 3 quarters · filed 2026-05-11 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $289.00K derived: sum of 2 quarters · filed 2026-03-30 | $397.00K 10-K · filed 2026-03-30 | |
| 2025-09-30 | $289.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $397.00K 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $108.00K 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $83.00K derived: sum of 2 quarters · filed 2026-03-30 | $296.00K derived: sum of 3 quarters · filed 2026-03-30 | $481.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $296.00K derived: sum of 2 quarters · filed 2025-11-05 | $481.00K 10-Q · filed 2025-11-05 | $554.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $213.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $398.00K 10-Q · filed 2025-08-14 | $471.00K derived: sum of 3 quarters · filed 2025-08-14 | $474.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $185.00K 10-Q · filed 2025-05-12 | $258.00K derived: sum of 2 quarters · filed 2025-05-12 | $261.00K derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | $73.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $76.00K derived: sum of 2 quarters · filed 2025-03-24 | $115.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $42.00K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $39.00K 10-Q · filed 2024-08-12 | |||
| 2022-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $672.00K 10-K · filed 2024-03-11 | ||
| 2022-09-30 | $647.00K 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |